JOP20200044A1 - مثبط انتقائي egfr طافر exon 18 و/أو exon 21 - Google Patents
مثبط انتقائي egfr طافر exon 18 و/أو exon 21Info
- Publication number
- JOP20200044A1 JOP20200044A1 JOP/2020/0044A JOP20200044A JOP20200044A1 JO P20200044 A1 JOP20200044 A1 JO P20200044A1 JO P20200044 A JOP20200044 A JO P20200044A JO P20200044 A1 JOP20200044 A1 JO P20200044A1
- Authority
- JO
- Jordan
- Prior art keywords
- exon
- mutation
- selective inhibitor
- mutant egfr
- egfr selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
غير متوفر
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 | ||
| PCT/JP2018/032314 WO2019045036A1 (ja) | 2017-09-01 | 2018-08-31 | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20200044A1 true JOP20200044A1 (ar) | 2020-02-26 |
| JOP20200044B1 JOP20200044B1 (ar) | 2024-04-18 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2020/0044A JOP20200044B1 (ar) | 2017-09-01 | 2020-02-26 | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (ar) |
| EP (1) | EP3677266B1 (ar) |
| JP (1) | JP7065103B2 (ar) |
| KR (1) | KR102676530B1 (ar) |
| CN (2) | CN117159551A (ar) |
| AU (1) | AU2018325819B2 (ar) |
| CA (1) | CA3074418C (ar) |
| DK (1) | DK3677266T5 (ar) |
| ES (1) | ES2972895T3 (ar) |
| FI (1) | FI3677266T3 (ar) |
| HU (1) | HUE066587T2 (ar) |
| IL (1) | IL272929B2 (ar) |
| JO (1) | JOP20200044B1 (ar) |
| MX (1) | MX2020002296A (ar) |
| MY (1) | MY199676A (ar) |
| PH (1) | PH12020500419A1 (ar) |
| PL (1) | PL3677266T3 (ar) |
| PT (1) | PT3677266T (ar) |
| SG (1) | SG11202001861WA (ar) |
| TW (1) | TWI838345B (ar) |
| WO (1) | WO2019045036A1 (ar) |
| ZA (1) | ZA202001445B (ar) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018079310A1 (ja) | 2016-10-31 | 2018-05-03 | 大鵬薬品工業株式会社 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
| PL3677266T3 (pl) | 2017-09-01 | 2024-07-01 | Taiho Pharmaceutical Co., Ltd. | Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 |
| ES3033635T3 (en) * | 2018-12-28 | 2025-08-06 | Taiho Pharmaceutical Co Ltd | L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202515577A (zh) * | 2023-06-27 | 2025-04-16 | 日商大鵬藥品工業股份有限公司 | 患有具有ｅｇｆｒ畸變的非小細胞肺癌之個體的治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| EP1871773A1 (en) | 2005-03-17 | 2008-01-02 | Novartis AG | N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| EP1800675B1 (en) | 2005-12-23 | 2011-05-18 | N.V. Nutricia | Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia |
| PT2452940E (pt) | 2009-07-10 | 2015-02-27 | Taiho Pharmaceutical Co Ltd | Composto azabiciclo e seu sal |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| TW201309668A (zh) | 2011-01-07 | 2013-03-01 | Taiho Pharmaceutical Co Ltd | 新穎雙環式化合物或其鹽 |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| DK2722332T3 (en) | 2012-02-23 | 2016-06-20 | Taiho Pharmaceutical Co Ltd | Quinolylpyrrolopyrimidylforbindelse with concentrated ring or salt thereof. |
| KR20150119401A (ko) | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| BR112016003247B1 (pt) | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| PL3677266T3 (pl) | 2017-09-01 | 2024-07-01 | Taiho Pharmaceutical Co., Ltd. | Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 |
-
2018
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 MY MYPI2020001066A patent/MY199676A/en unknown
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja not_active Ceased
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active Active
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
-
2020
- 2020-02-26 JO JOJO/P/2020/0044A patent/JOP20200044B1/ar active
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
| MX2025004367A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| JOP20190073B1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| JOP20190186A1 (ar) | مركب كينازولين | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| TW201613644A (en) | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor | |
| EP3972684A4 (en) | SYSTEMS AND METHODS FOR TREATMENT OF TUMORS BY TARGETED NEUROSTIMULATION | |
| EP3793523B8 (en) | Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis | |
| EP4286013A3 (en) | Lrrc33 inhibitors and use thereof | |
| MX2026002367A (es) | Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| TW200628156A (en) | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases | |
| MX2022002607A (es) | Metodos de tratamiento. | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| MX2020013684A (es) | Formulaciones/composiciones que comprenden ibrutinib. | |
| PH12021552389A1 (en) | Quinoline derivatives and their use for the treatment of cancer | |
| EP4335508A3 (en) | (+)-azasetron for use in the treatment of ear disorders | |
| HK40083292A (en) | Methods and agents for treating solid tumor cancers | |
| HK40054274A (en) | Methods of detecting, preventing, reversing, and treating neurological diseases | |
| WO2018222432A8 (en) | A predictive biomarker for let-7 microrna-based therapeutics for the treatment of human cancer |